John J. Graham

发表

Impact of Dyspnea on Medical Utilization and Affiliated Costs in Patients with Acute Coronary Syndrome

M. Bonafede, Y. Jing, S. Deitelzweig, 2011, Hospital practice.

Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.

S. Parasuraman, K. Bell, M. Shah, 2015, Journal of managed care & specialty pharmacy.

Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.

M. Ward, K. Worley, J. G. Bergeson, 2015, Journal of managed care pharmacy : JMCP.

Coronary Artery Bypass Graft Surgery in Acute Coronary Syndrome: Incidence, Cost Impact, and Acute Clopidogrel Interruption

S. Johnston, Y. Jing, K. Bell, 2012, Hospital practice.

Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients

A. Amin, J. Trocio, Jay Lin, 2014, Journal of medical economics.

Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results

A. Amin, J. Trocio, Jay Lin, 2015, Journal of Thrombosis and Thrombolysis.

Resource Utilization and Health Care Costs Among Diabetics with Urinary Tract Infections in a Commercially Insured Population

S. Parasuraman, Yihua Xu, K. Bell, 2012 .

Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.

E. Buysman, M. Lacey, S. Deitelzweig, 2013, Clinical therapeutics.

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

A. Amin, Jay Lin, Y. Jing, 2012, Journal of medical economics.

Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials

A. Amin, Jay Lin, Y. Jing, 2014, Journal of Thrombosis and Thrombolysis.

Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin

J. Trocio, A. Farr, S. Johnston, 2014, Hospital practice.

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

A. Amin, Jay Lin, Y. Jing, 2013, Journal of medical economics.

Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population.

E. Buysman, M. Lacey, Y. Jing, 2013, Clinical therapeutics.

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks

A. Amin, Jay Lin, Y. Jing, 2013, Cardiology and Therapy.